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ABSTRACT
The NK group 2 member D (NKG2D) immune receptor is implicated in both human and mouse autoimmune diabetes.
However, the significance of NKG2D in diabetes pathogenesis has been unclear due to conflicting reports as to the
importance of this receptor in the NOD mouse model. In this study we demonstrate that NKG2D expression affects NOD
diabetes development by at least two previously undescribed, and opposing, mechanisms. First, we demonstrate that the
NKG2D ligand H60a is induced on activated NOD T cells, and that NKG2D–H60a interaction during CD8+ T cell differentiation
into CTLs generally decreases the subsequent CTL effector cytokine response. This corresponds to an increase in diabetes
development in NKG2D-deficient compared with wild-type NOD mice under microbiota-depleted conditions. Second, we
demonstrate that NKG2D promotes NOD diabetes development through interaction with the microbiota. Together these
findings reveal a previously undescribed role for NKG2D ligand expression by activated T cells in CTL development. Further,
they demonstrate that NKG2D has both diabetogenic and antidiabetogenic roles in NOD diabetes development.
ImmunoHorizons, 2017, 1: 198–212.
INTRODUCTION
Type 1 diabetes is an autoimmune disease occurring with
increasing frequency worldwide (1). In type 1 diabetes the
insulin-producing b cells in pancreatic islets are destroyed by
the immune system, resulting in a lifelong dependence on
supplemental insulin therapy and reduced life expectancy (2).
The cause of type 1 diabetes remains unknown; however, it is clear
that many factors contribute to disease development. T cells are
believed to play a signiﬁcant role in type 1 diabetes development,
with CD8+ T cells being critical to b cell destruction (3–6). Mouse
studies implicate the NK group 2 member D (NKG2D) immune
receptor in this diabetogenic CD8+ response (7–9). Further,
genetic linkage studies suggest an association between poly-
morphism in the gene encoding one of thehumanNKG2D ligands,
MHCclass I chain–relatedA (MICA), and type 1 diabetes (7, 8, 10).
NKG2D, encoded by the geneKlrk1, is expressed on all human
and mouse NK cells, all human CD8+ T cells, activated (but not
Received for publication March 30, 2017. Accepted for publication October 17, 2017.
Address correspondence and reprint requests to: Dr. Mary A. Markiewicz, University of Kansas Medical Center, 3901 Rainbow Boulevard, MS 3029, Kansas City, KS
66160. E-mail address: mmarkiewicz@kumc.edu
ORCIDs: 0000-0001-8904-8497 (S.R.); 0000-0003-3930-9630 (B.P.); 0000-0001-5685-8573 (M.A.M.).
1A.P.T. and N.S. contributed equally to this work.
This work was supported by Washington University Diabetes Research Center Grant P30 DK020579 (to M.A.M.), American Diabetes Association Grant 1-12-JF-41 (to
M.A.M.), National Institutes of Health Centers of Biomedical Research Excellence Grant P20GM104936 (to M.A.M.), the American Association of Immunologists Careers
in Immunology Fellowship Program (to N.S. and M.A.M.), and National Institutes of Health/Integrated Grants Management System Grant P30 GM103326 (flow cytometry
core).
Abbreviations used in this article: MICA, MHC class I chain–related A; NKG2D, NK group 2 member D; SPF, specific pathogen-free.
The online version of this article contains supplemental material.
This article is distributed under the terms of the CC BY 4.0 Unported license.
Copyright © 2017 The Authors
198 https://doi.org/10.4049/immunohorizons.1700011
RESEARCH ARTICLE
Adaptive Immunity
ImmunoHorizons is published by The American Association of Immunologists, Inc.
 by guest on N
ovem
ber 29, 2018
http://w
w
w
.im
m
unohorizons.org/
D
ow
nloaded from
 
naive) mouse CD8+ T cells, gd T cells, NKT cells, and rare CD4+
T cells in both human andmouse (11–17). NKG2D binds to a num-
ber of ligands that are not normally expressed by most healthy
tissues, but rather are induced by cellular stress (18). In
humans, the NKG2D ligands are MICA, MICB, and the
retinoic acid early transcript 1 family members (also known
as the UL16-binding proteins, or ULBP1-6) (11, 19–21). The
mouse NKG2D ligands are murine ULBP-like transcript 1, the
RAE1 protein family (RAE1a-e), and H60 proteins (H60a-c)
(22–26). All ligands induce similar signaling through NKG2D,
which in NK cells triggers granule release and cytokine
production (27). The function of NKG2D engagement in CD8+
T cells is less well understood, with both costimulatory as well
as TCR-independent functions, for NKG2D engagement on
T cells described (8, 11, 20, 21, 28–31).
In a previous study with the NODmousemodel, expression of
RAE1 was observed in the pancreatic islets, and Ab blockade of
NKG2D was found to inhibit CD8+ T cell inﬁltration and prevent
diabetes development (7). We subsequently showed that trans-
genic expressionofRAE1ebypancreaticb cells innonautoimmune
C57BL/6 mice caused recruitment of activated CD8+ T cells to
pancreatic islets (8). This suggested a mechanism by which
NKG2D ligand expression in the islets enhances diabetes devel-
opment in NOD mice. However, RAE1 gene expression was not
detected at any time during diabetes development in NOD
pancreatic islets in two other studies (32, 33). Additionally,
diabetes development in NOD mice genetically deﬁcient in
NKG2D was reported to be similar to that of wild-type NOD
mice (34). These conﬂicting results suggest that NKG2Dmay play
a more complex role in autoimmune diabetes development than
originally proposed, aﬀecting disease development through
multiple mechanisms.
In the current study, we compared eﬀector CTL responses
and diabetes development between NOD mice genetically
deﬁcient in NKG2D expression (Klrk12/2) and wild-type NOD
mice. In contrast to what was previously reported (7), we
detected the NKG2D ligand H60a, rather than RAE1, in the
pancreatic islets of NODmice. This expression was not on islet
cells, but on inﬁltrating T cells. We also found that both H60a
and NKG2D were expressed on NOD CD8+ T cells following
activation, and that NKG2D–H60a interaction via homotypic
CD8+ T cell contact during NOD CTL diﬀerentiation de-
creased eﬀector cytokine production by the CTL in vitro. This
corresponded with increased eﬀector cytokine production by
Klrk12/2 NOD CTL in vivo and increased diabetes develop-
ment in microbiota-depletedKlrk12/2NODmice. By contrast,
microbiota-replete Klrk12/2 mice had reduced diabetes de-
velopment compared with wild-type mice, showing a separate
eﬀect resulting from interactions between NKG2D and the
microbiota. Taken together, these results demonstrate that
NKG2D inﬂuences NOD diabetes development by at least two
separate, opposing mechanisms; NKG2D–ligand interaction
during CTL generation dampens the diabetogenic CTL re-
sponse, whereas NKG2D signaling induced by interaction with
the microbiota promotes diabetogenesis.
MATERIALS AND METHODS
Mice
NODmicewere purchased fromthe JacksonLaboratory.Klrk12/2
mice on the C57BL/6 background have been previously described
(35). TheKlrk12/2 allelewasmoved from theC57BL/6 to theNOD
genetic background using the speed congenics service of the
Washington University School of Medicine to generate Klrk12/2
NOD mice. By single nucleotide polymorphism analysis (per-
formed by DartMouse), these mice are 98% NOD, with the only
observed genomic region containing a continuous interval of
non–NOD-like single nucleotide polymorphisms found at the
expected site of the Klrk1 knockout allele. Experiments were
performedwithKlrk1+/+ (wild-type) andKlrk12/2NODlittermates
from Klrk1+/2 NOD interbreeding. Mice were housed under
speciﬁc pathogen-free (SPF) conditions in the Washington
University School of Medicine or University of Kansas Medical
Center animal facilities in accordancewith institutional guidelines.
Abs
Unconjugated anti-CD28 (Clone 37.51), anti-CD3e (Clone 2C11),
anti–mCD8-APC, anti–mCD4-BV786, anti–CD3e-PE-Cy7, anti-
mCD107 (LAMP1)-PE, anti–DX5-FITC, and anti-mCD45 were
purchased from BD Biosciences. Anti–H60-PE, anti–mNKG2D-
PE, rat IgG2a-PE, and rat IgG2b-PE were purchased from R&D
Systems.
Pancreatic islet isolation
Islets were puriﬁed with a Ficoll-Paque gradient by published
methods (36). Pancreata were minced and digested with collage-
nase IV (20mg/ml) (Sigma-Aldrich). The digested pancreata were
spun through a Ficoll-Paque gradient and the islets harvested.
RT-PCR
Single-cell suspensions were generated from whole pancreas,
puriﬁed islets, or from cells separated into CD45+ and CD452
fractions via magnetic bead separation (Invitrogen). Total RNA
was isolatedwithTrizol (Invitrogen) followedby theRNeasyMini
Kit (Qiagen) according to the manufacturers’ protocols. Reverse
transcription was performed with the SABiosciences RT2 First
StrandKit (QIAGEN). Real-time quantitative PCRwas performed
using the Power SYBR Green PCR Master Mix (Applied
Biosystems) and an ABI 7500 (Applied Biosystems) instrument,
according to the manufacturers’ instructions. Transcript levels
were normalized to 18S. The sequence of the primers used were:
RAE1 (all isoforms): forward 59-CCACCTGGGAATTCAACA-39
TC; reverse 59-TGA TCT TGG CTT TTC CTT GG-39; H60a:
forward 59-TGC CTG ATT CTG AGC CTT TTC-39 A; reverse 59-
ATT CACTGAGCACTGTCCATGTAG-39 AT; 18S: forward 59-
CCGCAGCTAGGAATAATGGAA-39; reverse59-CGAACCTCC
GAC TTT CGT TCT-39.
In vitro CTL generation
All cells were grown in IMDM (Cellgro) supplemented with 10%
deﬁned FBS (HyClone), penicillin-streptomycin-glutamine (Life
https://doi.org/10.4049/immunohorizons.1700011
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FIGURE 1. T cells within the pancreas of NOD mice express the NKG2D ligand H60a.
(A) Relative expression of RAE1 mRNA levels in isolated pancreatic islets from 20 wk old C57BL/6, NOD, or RIP-RAE1e (8) mice. (B) Relative
expression of H60a mRNA in the pancreas and spleen of 9 (expression set as 1-fold) and 14 wk old NODmice (mean6 STD). (C) Relative expression
of H60a mRNA in CD45+ and CD452 cells purified from isolated NOD pancreatic islets (mean 6 STD). The housekeeping gene 18S was used in all
experiments. (D) H60a expression on CD32 and CD3+ cells within the pancreas of a 12 wk old NOD mouse. (E) H60a expression on (Continued)
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Technologies), and b-mercaptoethanol (Sigma-Aldrich). For
activation of total splenocytes, spleens were harvested from
6 to 8 wk old SPF-housed NOD mice, passed through a 40 mm
cell strainer, and plated in a six-well dish at 1.5 3 107 cells per
well in 3 ml media and 1 mg/ml of plate-bound anti-CD3e
(2C11). For puriﬁed CD8+ T cells, cells were harvested from
spleens and lymph nodes of 6–8 wk old NOD mice, and
enriched by negative selection using magnetic beads (BD
Biosciences) according to the manufacturer’s protocol. CD8+
T cells were then plated at 3–53 106 cells per well in a six-well
dish with 1 mg/ml plate-bound anti-C3e (2C11) and soluble
anti-CD28 (37.51). The cells were allowed to expand for 5 d and
split as needed.
Cytokine analysis
In vitro. CTLwere harvested and plated at 13 105 cells perwell in
100 ml of fresh media in 96-well plates precoated with anti-CD3
(2C11) at the stated concentrations. Cells were incubated at 37°C
for 20 h. Supernatant was then collected and cytokines were
analyzed using the Mouse Inﬂammation Cytometric Bead Array
kit (BD Biosciences) and an LSR II (BD Biosciences). Data were
quantiﬁed using FCAP array software (BD Biosciences).
In vivo. Total CD8+ T cells were puriﬁed from spleens and lymph
nodes of 6–8 wk oldKlrk12/2 or wild-type NODmice by negative
selection using magnetic beads (BD Biosciences) according to
the manufacturer’s protocol. Isolated Klrk12/2 and wild-type
CD8+ T cells were then labeled with eFluor 670 (eBioscience)
and CFSE (Thermo Fisher Scientiﬁc), respectively. The
labeled cells were then mixed 1:1 and adoptively transferred
via retro orbital injection into 6–8 wk old wild-type NOD
recipient mice (Supplemental Fig. 2A). Total splenocytes were
harvested after 7 d, incubated for 4–6 h in completemediawith
GolgiPlug protein transport inhibitor (BD Biosciences),
followed by ﬁxation and permeabilization using BD Cytoﬁx/
Cytoperm (BD Biosciences) according to the manufacturer’s
directions. Cells were then stained overnight at 4°C with anti-
mouse TNF-a (BD Pharmingen), anti-mouse IFN-g (BD
Pharmingen), and anti-mouse CD8 (BioLegend), and analyzed
by ﬂow cytometry. Transferred CD8+ T cells were analyzed by
gating on live lymphocytes based on forward and side scatter,
CD8+ cells, then either eFluor 670+ or CFSE+ cells.
Lamp-1 granule release analysis
CTLwere plated at 13 105 in 100ml fresh media in 96-well plates
precoated with anti-CD3e (2C11) at the stated concentrations.
Before plating, PE-conjugated anti-CD107a was added to the cells
at 4 ml/ml. Cells were incubated at 37°C for 3 h before being
washed, ﬁxed in 2% paraformaldehyde, and assessed for LAMP1
staining by ﬂow cytometry.
Antibiotic treatment of mice
A solution of 0.5 g/l vancomycin (Sigma-Aldrich), 1 g/l neomycin
(Sigma-Aldrich), 1 g/l ampicillin (Sigma-Aldrich), and 1 g/l metro-
nidazole (Sigma-Aldrich) was made in grape KoolAid. This so-
lution was mixed with Dietgel Boost (ClearH2O) and crushed
food pellets.
Klrk12/2 and wild-type NOD littermates were exclusively fed
this antibiotic mixture beginning at weaning until euthanasia.
Sequencing of the 16S rRNA genes present in feces conﬁrmed that
the Firmicutes and Bacteroidetes populations, the two predomi-
nant bacteria phyla present in the intestine, were reduced 94–99%
within 4 wk of antibiotic treatment.
Diabetes determination
In all experiments the age of diabetes development was deﬁned as
the age at which the ﬁrst of two consecutive blood glucose
measurements$250 mg/dl was obtained.
Statistical analysis
Data were analyzed using a two-tailed unpaired Mann–Whitney
U test, one-tailedWilcoxon test, or two-way ANOVA as described
in the ﬁgure legends. All statistical analyseswere performed using
GraphPad Prism.
RESULTS
The NKG2D ligand H60a is expressed on infiltrating T cells
within the pancreas of NOD mice
Wesetout to better characterize the role ofNKG2Dand its ligands
in NOD diabetes. We ﬁrst examined wild-type NOD pancreatic
islets for NKG2D ligand expression. A previous report described
the expression of RAE1 family members in the pancreatic b-islet
cells of NOD mice, and suggested that this expression targeted
b-islet cells for autoimmune destruction (7). Therefore, we ﬁrst
looked for RAE1 mRNA expression in the pancreatic islets of our
NOD mice. We used RIP-RAE1e mice, which constitutively
express RAE1e in the pancreatic islets (8), as a positive control.
However, wewere unable to detect RAE1mRNA in the pancreatic
islets of wild-type NOD mice in our colony (Fig. 1A). We next
looked for expression of the other NKG2D ligand expressed in
NODmice,H60a.We found signiﬁcant expression ofH60amRNA
in both the pancreas and spleen of NOD mice by 12 wk of age
(Fig. 1B, 1C).
To determine whether H60awas expressed within pancreatic
islets, as well as which cells expressed H60a, we compared H60a
mRNA levels between immune (CD45+) andnonimmune (CD452)
cells present within isolated islets from 12 wk old mice. These
analyses revealed H60a mRNA was expressed in the CD45+
immune cells, but not the CD452 islet cells (Fig. 1C). Finally, we
CD4+ and CD8+ T cells within the pancreas of a 12 wk old NOD mouse. The mean fluorescence intensity of staining is shown. Data are
representative of at least three independent experiments. **p # 0.01 in two-tailed unpaired Mann–Whitney U test. ND, not detected.
https://doi.org/10.4049/immunohorizons.1700011
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FIGURE 2. NOD T cells express H60a upon activation.
H60a expression on CD4+ and CD8+ T cells following activation of NOD splenocytes with anti-CD3e Ab. The mean fluorescence intensity of
staining is shown. H60a expression was assessed on CD4+ and CD8+ gated live cells. Data are representative of at least four independent
experiments.
https://doi.org/10.4049/immunohorizons.1700011
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FIGURE 3. NOD CD8+ T cells express both H60a and NKG2D upon activation.
Expression of (A) H60a and (B) NKG2D on CD8+ T cells purified from 6 to 8 wk old Klrk12/2 and wild-type NOD mice activated with anti-CD3e and
anti-CD28 Abs. Mean fluorescence intensity of staining is shown. Data are representative of at least four independent experiments.
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FIGURE 4. Altered cytokine production by Klrk12/2 NOD CTL.
(A) Secretion of TNF-a, IFN-g, and IL-10 (mean 6 STD) by in vitro–generated Klrk12/2 and wild-type CTL stimulated with the indicated
concentrations of anti-CD3e Ab. Data are representative of at least six independent experiments. (B) Representative flow cytometry plots showing
intracellular staining of TNF-a and IFN-g in Klrk12/2 and wild-type NOD CD8+ T cells 1 wk after cotransfer into a wild-type NOD adoptive transfer
recipient mouse. (C) Combined results (mean 6 SEM) from transfers into eight mice from three independent experiments showing the (Continued)
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determined by ﬂow cytometric analysis that the major cells
expressing H60a were pancreas-inﬁltrating T cells (Figs. 1D, 1E).
NOD CD8+ T cells express NKG2D and H60a
upon activation
Wenext set out to determine the role of H60a expression byNOD
T cells. We ﬁrst characterized the expression of H60a on splenic
T cells in young (6–8 wk old) NOD mice. We observed low but
detectableH60a expression on freshly isolated splenicT cells (Fig.
2).We testedwhetheractivationwould increase this expressionby
stimulating NOD splenocytes in vitro with anti-CD3 Ab. H60a
expression increased substantially on both CD4+ and CD8+ T cells
following activation and remained elevated through day 5 of
culture (Fig. 2).
In addition to H60a, activated NOD CD8+ T cells express
NKG2D (7). Therefore, we determined the time course of both
H60a and NKG2D expression after initial TCR activation of NOD
CD8+ T cells in vitro. CD8+ T cells were puriﬁed from the spleens
and lymphnodes of 6–8wkoldKlrk12/2 andwild-typeNODmice.
NKG2D and H60a expression was assessed at the time of cell
percent TNF-a or IFN-g positive Klrk12/2 and wild-type NOD CD8+ T cells 1 wk after cotransfer into wild-type NOD adoptive transfer recipient
mice. **p # 0.01, ***p # 0.001, ****p # 0.0001 in two-tailed unpaired Mann–Whitney U test.
FIGURE 5. Blockade of NKG2D–H60a interaction during NOD CTL differentiation results in increased CTL effector cytokine production.
Secretion of TNF-a, IFN-g, and IL-10 by in vitro–generated Klrk12/2 and wild-type CTL stimulated with the indicated concentrations of anti-CD3e
Ab in the presence of an anti-H60a or isotype control Ab. Data are representative of at least six independent experiments. *p # 0.05, ***p # 0.001,
****p # 0.0001 in two-tailed unpaired Mann–Whitney U test.
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isolation and daily following activation with anti-CD3 and anti-
CD28 Abs. Similar to what we observed with whole splenocytes
(Fig. 2), a low levelofH60awasdetecteddirectly exvivo, increased
after TCR activation, and continued through day 5 (Fig. 3A). This
expression was unaﬀected by Klrk1 (Fig. 3A). In wild-type mice,
NKG2D became detectable on day 2 and persisted through day 5
(Fig. 3B).
NKG2D expression alters NOD CTL effector cytokine
responses in vitro and in vivo
NKG2Dengagement by ligands expressedon target cells enhances
CTL eﬀector function induced by TCR engagement by Ag
expressed on the same target cells (11, 28). Given our ﬁnding that
NOD CTL coexpress NKG2D and the NKG2D ligand H60a, we
hypothesized NKG2D–H60a interaction via homotypic CD8+
T cell contact could similarly alterNODCTL eﬀector function. To
test this, we activated puriﬁedKlrk12/2 andwild-type NODCD8+
Tcellswithanti-CD3andanti-CD28Abs invitro andallowedthem
to diﬀerentiate for 5 d. Cytokine production and lytic granule
release by the CTL were then assessed after restimulation with
various concentrations of plate-bound anti-CD3 Ab to mimic
target cell recognition.
In the absence of stimulation, or with a low concentration of
anti-CD3 Ab, Klrk12/2 CTL produced signiﬁcantly more IFN-g,
TNF-a, and IL-10 compared with wild-type CTL (Fig. 4A,
Supplemental Fig. 1A). With a higher concentration of anti-CD3
Ab, Klrk12/2 CTL also produced greater amounts of TNF-a and
IL-10 (Fig. 4A, Supplemental Fig. 1A). At this higher level of
stimulation, IFN-gproductionbyKlrk12/2CTLwas lower insome
experiments compared with wild-type CTL; however, this did not
reach statistical signiﬁcancewhendata frommultiple experiments
were combined (Fig. 4A, Supplemental Fig. 1A). In contrast to this
eﬀect on cytokine production, no change in lytic granule release
was observed (Supplemental Fig. 1B). To determine if NKG2D
expression similarly aﬀected NOD CD8+ T cell cytokine pro-
duction in vivo, we puriﬁed CD8+ T cells from Klrk12/2 or wild-
type NOD mice and labeled them with eFluor 670 or CFSE,
respectively. Without providing exogenous TCR activation, we
adoptively transferred a 1:1 mixture of these cells into wild-type
NOD recipient mice (Supplemental Fig. 2A). After 1 wk, Klrk12/2
cells recovered from the spleen produced more TNF-a and
IFN-g than wild-type cells recovered from the same spleen (Fig.
4B, 4C). Together, these results demonstrate that expression of
NKG2D byNODCD8+ T cells generally reduces eﬀector cytokine
production by these cells.
NKG2D--H60a interaction during NOD CTL differentiation
dampens diabetogenic cytokine production
To assess whether the increased cytokine production by Klrk12/2
CTL was the result of a loss of NKG2D interaction with H60a
during the eﬀector response, we included a blocking Ab against
H60aduring eﬀectorCTL stimulation.However, this blockade did
not aﬀect cytokine secretion by any of the CTLs (Supplemental
Fig. 3A, 3B). This led us to hypothesize that NKG2D–H60a
interaction during CTL diﬀerentiation, rather than during
the eﬀector CTL response, was responsible for the altered
cytokine production by Klrk12/2 CTL. To test this, we added
anti-H60a blocking Ab at the beginning of the T cell culture.
This resulted in increased TNF-a, IL-10, and IFN-g by wild-
type CTL when the cells were stimulated with a low con-
centration of anti-CD3 Ab (Fig. 5, Supplemental Fig. 4). With a
higher concentration of anti-CD3 Ab, H60a blockade also
resulted in greater production of TNF-a and IL-10, but lower
or similar production of IFN-g, by wild-type CTLs (Fig. 5,
Supplemental Fig. 4). Conﬁrming this eﬀect of H60a blockade
was dependent on NKG2D expression, no diﬀerence in cytokine
production was observed between CD3-stimulated anti–H60a-
and isotype control-treated Klrk12/2 CTL (Fig. 5, Supplemental
Fig. 4). The similar eﬀect of NKG2D deﬁciency (Fig. 4A,
Supplemental Fig. 1A) and H60a blockade during CTL diﬀeren-
tiation (Fig. 5, Supplemental Fig. 4) demonstrates that NKG2D–
H60a interaction via homotypic CD8+ T cell contact during CTL
FIGURE 6. NKG2D expression affects NOD diabetes development and is protective in microbiota-depleted NOD mice.
Cumulative diabetes incidence in (A) female wild-type (n = 59), antibiotic (ABX)-treated wild-type (n = 17), Klrk12/2 (n = 30), ABX-treated Klrk12/2
(n = 13) and (B) male wild-type (n = 36), ABX-treated wild-type (n = 10), and Klrk12/2 (n = 26) and ABX-treated Klrk12/2 (n = 14) NOD mice. **p #
0.002, ***p # 0.001, ****p # 0.0001 in two-way ANOVA.
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FIGURE 7. Immune cell populations, activation, and NKG2D and H60a expression in the spleen of untreated and antibiotic-treated Klrk1+/+ and
Klrk12/2 NOD mice.
(A) Percentage of total splenocytes in 12 wk old wild-type and Klrk12/2 NOD mice with or without antibiotic that were CD32 CD49b+ (NK cells),
CD32 CD49b2 (non-T or NK cells), or CD3+ (T cells). (B) Percentage of splenic T cells in (A) that were CD4+ and CD8+. (C) CD62L and CD44
expression by splenic CD4+ T cells in (A). (D) CD62L and CD44 expression by splenic CD8+ T cells in (A). (E–G) Percentage of splenic (Continued)
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diﬀerentiation alters the NOD CTL eﬀector cytokine response,
generally reducing production.
NKG2D enhances diabetes development in SPF-housed
NOD mice
Expression of TNF-a, IFN-g, and IL-10 within the islets all
enhance NOD insulitis and diabetes development (37). Given the
increased production of these cytokines by Klrk12/2 CTL, we
predicted that NKG2D expression would have a protective role in
NOD diabetes development. To test this, we ﬁrst compared
diabetes development between Klrk12/2 and wild-type NOD
littermates housed under SPF conditions. As is well characterized
in the NOD model (38–40), there was greater diabetes develop-
ment in the female compared with the male mice. However, in
both sexes, the Klrk12/2mice exhibited slower diabetes develop-
ment compared with wild-type mice (Fig. 6).
NKG2D decreases diabetes in NOD mice treated with broad-
spectrum antibiotics
The reduced diabetes development inKlrk12/2NODmicewas
inconsistent with our ﬁnding that NKG2D–H60a interaction
decreases CTL eﬀector function. This suggested there is an
additional prodiabetic role for NKG2D signaling in disease
development. We hypothesized that this role may be via
interaction with the microbiota. This was based on the fact
that Klrk12/2 mice are deﬁcient in B1a B cells (41), which are
believed to play a major role in shaping the microbiota
composition via IgA production (24), and that NOD diabetes
development is sensitive tomicrobiota alterations (40, 42–44).
To test this hypothesis, we compared the eﬀect on diabetes
development of an antibiotic treatment that largely depletes
the intestinal microbiota (45–47). Comparedwith SPF-housed
wild-type mice, antibiotic-treated wild-type NOD mice
exhibited reduced diabetes development (Fig. 6). By contrast,
diabetes development in Klrk12/2 mice was unchanged by
antibiotic treatment (Fig. 6). These results demonstrate that an
interaction exists between NKG2D and the microbiota present
in our SPF mouse colony, which enhances NOD diabetes
incidence. By contrast, with antibiotic treatment, diabetes
development was enhanced in Klrk12/2 compared with wild-
typeNODmice (Fig. 6). Similar to SPF-housedmice, adoptively
transferred Klrk12/2 cells recovered from the spleen of
antibiotic-treated wild-type mice produced more TNF-a and
IFN-g compared with adoptively transferred wild-type cells
(Supplemental Fig. 2B). These results support our ﬁndings that
NKG2D plays a protective role during NOD diabetes develop-
ment via interaction with H60a during CTL diﬀerentiation.
We next compared the immune cell populations present in the
spleen and pancreas of wild-type and Klrk12/2 mice under both
SPFandantibiotic-treated conditions. Antibiotic treatment didnot
signiﬁcantly change NKG2D or H60a expression (Figs. 7G, 8G),
and there was no diﬀerence in CD69 expression on immune cells
in the pancreas or spleen between wild-type and Klrk12/2 mice
under either condition (Figs. 7E, 8E). Antibiotic treatment did
result in a decrease inCD4+T cells in both the pancreas and spleen
(Figs. 7B, 8B), and altered the ratio of eﬀector to central memory
CD4+T cells in the pancreas (Fig. 8C). Speciﬁcally,with antibiotics
therewere fewer eﬀectorCD4+T cells (CD44+CD62L2) andmore
centralmemory CD4+ T cells (CD44+CD62L+) in the pancreas in
both wild-type and Klrk12/2mice (Fig. 8C). There was a similar
increase in central memory CD8+ T cells in the pancreas;
however, unlike the CD4+ T cell population, there was no
corresponding decrease in eﬀector CD8+ T cells (Fig. 8D). These
data demonstrate that there were fewer eﬀector T cells in the
pancreas of the antibiotic-treated mice. This corresponds with
the reduced diabetes development in these mice compared with
SPF-housed wild-type mice (Fig. 6), as well as the increased
ability to observe the protective role of NKG2D in antibiotic-
treated mice (Fig. 6).
DISCUSSION
In this studywedemonstrate thatNKG2Dexpression aﬀectsNOD
diabetes development via two previously undescribed mecha-
nisms.First,wedemonstrate that interactionbetweenNKG2Dand
H60a, both expressed on diﬀerentiating CTL, reduces the pro-
duction of eﬀector cytokines byNODCTL. This correspondswith
decreased diabetes development in antibiotic-treated Klrk12/2
NOD mice. Second, we showed that NKG2D inﬂuences NOD
diabetes development via interaction with the microbiota.
NKG2D is implicated in the development of autoimmune
diabetes inbothhumansandmice (7–10); however, adeﬁnitive role
for NKG2D in this disease has not been established. Much of this
uncertainty has been due to seemingly conﬂicting results in the
NOD mouse model. Previous reports have demonstrated that
NKG2D either promotes NOD diabetes (7) or has little eﬀect (34).
In particular, Ogasawara et al. (7) suggested that expression of the
NKG2D ligand RAE1 in pancreatic islets targets islet b cells for
NKG2D-mediated destruction. Our later ﬁnding that transgenic
expressionofRAE1by isletb cellsdrove immunecell inﬁltrationof
pancreatic islets in the non-autoimmune C57BL/6 background
seemed to support the feasibility of this model (8). In the current
study, however, we did not detect expression of RAE1 mRNA, or
any other NKG2D ligand, by CD452 cells in pancreatic islets. This
ﬁnding is consistent with other reports that found no RAE1
mRNA (32, 33), or protein (33) expressed byNOD islet cells. These
diﬀering reports of RAE1 expression may be a result of variance
between NOD mouse colonies due to gut microbial inﬂuence or
genetic drift (40, 42, 48). A report by Adlercreutz et al. (49) did
show expression of H60a mRNA in the pancreatic islets of 13 wk
old NOD and BALB/c mice, but did not distinguish between
populations in (A) and (B) that expressed (E) CD69, (F) H60a, or (G) NKG2D. Data are combined results (mean6 SEM) of at least four mice per group.
*p # 0.05, **p # 0.01 in two-tailed unpaired Mann–Whitney U test.
https://doi.org/10.4049/immunohorizons.1700011
208 A PROTECTIVE ROLE FOR NKG2D–H60A INTERACTION IN NOD DIABETES ImmunoHorizons
 by guest on N
ovem
ber 29, 2018
http://w
w
w
.im
m
unohorizons.org/
D
ow
nloaded from
 
FIGURE 8. Immune cell populations, activation, and NKG2D and H60a expression in the pancreata of untreated and antibiotic-treated Klrk1+/+
and Klrk12/2 NOD mice.
(A) Percentage of cells isolated from the pancreata of 12 wk old wild-type and Klrk12/2 NOD mice with or without antibiotic that were CD32 CD49b+
(NK cells), CD32 CD49b2 (non-T or NK cells), or CD3+ (T cells). (B) Percentage of T cells in (A) that were CD4+ and CD8+. (C) CD62L and CD44
expression by CD4+ T cells in (A). (D) CD62L and CD44 expression by CD8+ T cells in (A). (E–G) Percentage of populations in (A) and (B) that (Continued)
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immune and nonimmune cells. This is consistent with the H60a
mRNA expression observed in our study.
Our observation of robust H60a expression by activated NOD
CD8+ T cells was not anticipated, but is consistent with earlier
reports. H60a mRNA was previously shown to be expressed in
healthy NOD tissues and by NODNK cells (49, 50). Similar to the
NODmouse, BALB/c immune cells express H60a (23, 25, 51), and
mRNA encoding thisNKG2D ligandwas shown to be upregulated
in BALB/c T cells upon activation (52). Likewise, human T cells
also express NKG2D ligands upon activation (53–55).
Constitutive NKG2D ligand expression decreases NKG2D
surface expression on NK and CD8+ T cells (18, 56, 57). Poor
NKG2Dexpressionhasbeenpreviously reportedonNODNKcells
(50), which correlated with RAE1 expression by these cells (50).
Similarly, thehigh level ofH60aexpressiononNODCD8+Tcells is
likely responsible for the low surface expression of NKG2D we
observed on these cells. However, our results clearly show that
this low NKG2D expression has functional relevance to CTL
diﬀerentiation.
To date, the function of NKG2D in CD8+ T cells has largely
been studied in diﬀerentiated CTLs. These studies have generally
shown a costimulatory role for NKG2D, enhancing TCR-
stimulated eﬀector function (11, 28, 58) or memory formation
(59, 60). The eﬀects of NKG2D signaling in the absence of TCR
engagement are not well understood, but have been shown to
induce immune synapse formationbymouseCTLs (28)andMHC-
unrestricted killing by cytokine-activated human CTLs (61).
Therefore, our ﬁnding that there is a role for NKG2D–H60a
interactionduringCD8+T cell diﬀerentiation intoCTLdescribes a
new mode of NKG2D–ligand interaction, which dampens, rather
than enhances, later CTL responses.
In our in vitro experiments, there was a consistent decrease in
TNF-a, IL-10, and IFN-g production by CTL with either genetic
knockout of NKG2D or Ab blockade of H60a with low levels of
stimulation. At the highest level of stimulation, IFN-g production
was signiﬁcantly decreased in anumber of experiments (Figs. 4, 5).
This decrease could potentially reﬂect a diﬀerent cytokine re-
sponse at very high levels of TCR stimulation. However, because
this decrease was not signiﬁcant when data from all experiments
were combined (Supplemental Figs. 1, 3), we did not investigate
this further. Additionally, the consistently enhanced production of
IFN-g byKlrk12/2 adoptively transferredCD8+Tcells in vivo (Fig.
4B, 4C) suggests that low to medium levels of TCR stimulation
more closely reﬂect in vivo conditions.
When we assessed diabetes incidence in Klrk12/2 and wild-
type NODmice, our results indicated a diﬀerent eﬀect of NKG2D
genotype ondiabetes incidence depending uponwhether themice
were treated with microbiota-depleting antibiotics. Under SPF
housing conditions, we found a detrimental role for NKG2D in
NOD diabetes development. By contrast, when animals were
treated with antibiotics, wild-type NODmice had delayed disease
compared with Klrk12/2 mice. This diﬀerential eﬀect revealed a
separate protective role for NKG2D. In addition, the lack of an
eﬀect of antibiotic treatment ondisease incidence inKlrk12/2mice
provides evidence for NKG2D genotype–dependent changes in
the microbiota aﬀecting NOD diabetes incidence. Antibiotic-
treatment resulted in a decrease in eﬀector T cells in the pancreas.
This is a probablemechanismbywhich diabetes developmentwas
decreased in antibiotic-treated compared with SPF-housed wild-
typemice. Further, it is likely that this decrease in eﬀectorT cells is
responsible for the increased ability to observe the protective role
of NKG2D in diabetes development with antibiotic treatment.
Taken together, our results lead us to propose a detrimental
inﬂuence of NKG2D on diabetes development in the gut, which
involves the microbiota, and a separate eﬀect independent of
microbiota in which NKG2D dampens the NOD CTL cytokine
response.
We observed the well-established sexual dimorphism in NOD
diabetes incidence, with increased rates of diabetes in females
compared with males (38–40). Within SPF-housed or antibiotic-
treated groups, however, the eﬀect of NKG2D was consistent
between males and females. The mechanism by which NKG2D
promotes NOD diabetes through interactions with microbiota
was not explored in the current study, but warrants further in-
vestigation.Thismaybedue to a lackofB1a cells in thesemice (41),
or interaction of other immune cells with NKG2D ligands, which
are constitutively expressed by intestinal epithelial cells (62–65).
Additionally, further work remains to conclusively attribute the
protective eﬀect of NKG2D genotype in antibiotic-treated animals
to the eﬀects of NKG2D–H60a interactions betweenCD8+ T cells.
Although our data do support this hypothesis, a deﬁnitive answer
awaits the generation of a NOD H60a2/2mouse, as well as CD8+
T cell conditional NOD NKG2D2/2 and NOD H60a2/2 animals.
Finally, our model of opposing pro- and antidiabetic eﬀects of
NKG2D suggests that a lack of consensus from previous studies
concerning the role of NKG2D in NOD diabetes may be the result
of variation in cohousing practices and diﬀerences in microbiota
between mouse colonies.
In summary,we found thatNKG2D–H60a interactionbetween
CD8+ T cells during NOD CTL diﬀerentiation in vitro resulted in
decreased production of diabetogenic cytokines upon subsequent
CTL activation. To our knowledge, this is the ﬁrst report of a role
for NKG2D–NKG2D ligand interaction during diﬀerentiation
of mouse CD8+ T cells into CTL rather than during the eﬀector
phase of diﬀerentiated CTL. Furthermore, these results describe
a functional role for NKG2D ligand expression by healthy murine
CD8+ T cells. Finding that NKG2D is protective in animals with
depletedmicrobiota correlates with NKG2D signaling resulting in
reduced cytokine production by NOD CTL. The additional
observation that microbiota-depleting antibiotics profoundly
expressed (E) CD69, (F) H60a, or (G) NKG2D. Data are combined results (mean 6 SEM) of at least four mice per group. *p # 0.05, **p # 0.01 in two-
tailed unpaired Mann–Whitney U test.
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aﬀectedNODdiabetesdevelopment inwild-type,butnotKlrk12/2,
animals demonstrates a separate eﬀect in which NKG2D-
dependent alterations in the microbiota promote disease devel-
opment. Additionally, these data may have broader implications
for the role of NKG2D–ligand interaction between T cells in
modulating CD8+ T cell responses in both mice and humans.
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